Breaking Down the Impact of SERENA-6 for Some With Breast Cancer

Breaking Down the Impact of SERENA-6 for Some With Breast Cancer

Dr. Joshua K. Sabari and Dr. Julia E. McGuinness discussed the SERENA-6 trial and its outcomes for patients with ESR1-mutated HR+/HER2— breast cancer.

Arvinas Announces Submission of New Drug Application to US FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer

Arvinas, Inc. announced the submission of a New Drug Application to the US FDA with its partner Pfizer Inc., for vepdegestrant for the treatment of patients with ER+/HER2- ESR1-mutated advanced or metastatic breast cancer previously treated with endocrine-based therapy. [Arvinas, Inc.] Press Release

ASCO 2025 Metastatic Breast Cancer Updates | Breast Cancer Research Foundation

Investigators presented several potentially practice-changing treatment advances for these patientsAt the annual meeting of the American Society of Clinical Oncology (ASCO), there was a keen focus on metastatic breast cancer (MBC). Thanks to research, more patients are living with MBC than ever before—but it remains incurable. Investigators are expanding our understanding of MBC and continually looking for new strategies and treatments to give p…